ArticleCancer management and research2022

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.

Nobuki Furubayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.